Bristol-Myers Squibb Co. slashed its guidance for the year as the drugmaker contends with dimmed prospects for its top cancer drug after major setbacks during the final quarter of the year.
from WSJ.com: US Business http://ift.tt/2knDpN8
via IFTTT
No comments:
Post a Comment